scholarly journals Reasons and mechanisms of organ remodeling in kidney, cardiovascular diseases and bronchialasthma

2009 ◽  
Vol 7 (4) ◽  
pp. 46-53
Author(s):  
V I Pytsky
Keyword(s):  
Cardiovascular Diseases ◽  
Bronchial Asthma ◽  
Liver Diseases ◽  
Main Mechanism ◽  
Excessive Function ◽  
Tissue Fibrosis ◽  
Common Process

Organ and system remodeling is a very common process and is observed in some kidney, cardiovascular, GI, liver diseases and bronchial asthma. Main mechanism is tissue fibrosis in organs with excessive function.

scholarly journals Management of Medically Compromised Prosthodontic Patients

2022 ◽  
Vol 2022 ◽  
pp. 1-11
Author(s):  
Pratistha Ghimire ◽  
Pramita Suwal ◽  
Bishal Babu Basnet
Keyword(s):  
Chronic Kidney Disease ◽  
Cardiovascular Diseases ◽  
Liver Diseases ◽  
Pulmonary Diseases ◽  
Endocrine Disorders ◽  
Systemic Diseases ◽  
Treatment Length ◽  
Length Of Treatment ◽  
Medical Evaluation ◽  
Neurologic Disorders

The medical evaluation of patients considering prosthodontic treatment is a vital step in the treatment planning. The prosthodontist should be able to assess the inherent risks associated with the treatment of patients with systemic conditions. Many factors are associated with evaluating the patient’s health status and risk including the patient’s current and past medical and dental history, current and past use of medications, type of treatment, length of treatment, invasiveness of treatment, and degree of urgency of treatment. In this article, some of the systemic diseases like arthritis, cardiovascular diseases, endocrine disorders, hematologic and oncologic disease, neurologic disorders, bone disorders, pulmonary diseases, liver diseases, and chronic kidney disease that commonly affect aged individuals are reviewed. The prosthodontic considerations that should be taken care of while managing patients with these systemic conditions will also be discussed.

scholarly journals The influence of diets on plasma homocysteine levels in felines

2020 ◽  
Vol 77 (2) ◽  
pp. 85
Author(s):  
Mihaela COTUL ◽  
Mihai CERNEA ◽  
Laura CĂTANĂ ◽  
Sanda ANDREI
Keyword(s):  
Veterinary Medicine ◽  
Cardiovascular Diseases ◽  
Clinical Studies ◽  
Liver Diseases ◽  
Plasma Homocysteine ◽  
Nutritional Requirements ◽  
Group Test ◽  
Quality Food ◽  
The Relationship

Epidemiological and clinical studies in humans established the relationship between homocysteine (Hcy) level in plasma and cardiovascular, kidney and liver diseases. In veterinary medicine, the results regarding Hcy are questionable due to conflicting and rare data. The relationship between the metabolism of Hcy and the nutritional principles of different diets can lead in the future to a real prevention of cardiovascular diseases by simply managing the food of predisposed and elderly animals. The present study aims at comparing two types of diets over a period of 9 months (commercial CD and homemade HMD) on the feline plasma Hcy. Analyzing comparatively the results obtained from the determination of serum Hcy values on the initial diets (t0) and after 9 months of diet (t1), we can observe the decrease of these values both in group test I, which switched from a CD to a HMD, as well as in group test 2, which maintained a CD but switched from a lower quality food to a higher quality one. This fact demonstrates not only the benefits of a home-made diet, but also the need to diversify and combine the commercial one to satisfy the nutritional requirements of the feline organism.

scholarly journals The agreed experts’ position of the Eurasian Association of Therapists on tactics of management of patients with comorbid pathology infected with SARS-Cov-2

2020 ◽  
Vol 92 (9) ◽  
pp. 108-124
Author(s):  
G. P. Arutiunov ◽  
E. I. Tarlovskaia ◽  
N. A. Koziolova ◽  
M. V. Boldina ◽  
M. M. Batiushin ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Chronic Obstructive Pulmonary Disease ◽  
Chronic Kidney Disease ◽  
Drug Interaction ◽  
Cardiovascular Diseases ◽  
Kidney Disease ◽  
Pulmonary Disease ◽  
Bronchial Asthma ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

The agreement of experts of the Eurasian Association of Therapists (EAT) discusses pathogenesis and treatment of COVID-19. Modern data on the characteristics of cardiovascular, kidney, respiratory damage in SARS-infected CoV-2 are presented. The tactics of managing patients initially having cardiovascular diseases, diabetes mellitus, chronic obstructive pulmonary disease, bronchial asthma, chronic kidney disease are discussed in detail. The article presents data on drug interaction of drugs.

scholarly journals Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review

Foods ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 340 ◽  
Author(s):  
Xiao Meng ◽  
Jing Zhou ◽  
Cai-Ning Zhao ◽  
Ren-You Gan ◽  
Hua-Bin Li
Keyword(s):  
Clinical Trials ◽  
Cardiovascular Diseases ◽  
Chronic Diseases ◽  
Liver Diseases ◽  
Molecular Mechanisms ◽  
Health Benefits ◽  
Experimental Studies ◽  
Bioactive Compound ◽  
Protective Effects ◽  
Epidemiological Surveys

Resveratrol is a bioactive compound in many foods. Since its anticancer activity was reported in 1997, its health benefits have been intensively investigated. Resveratrol has antioxidant, anti-inflammatory, immunomodulatory, glucose and lipid regulatory, neuroprotective, and cardiovascular protective effects, therefore, can protect against diverse chronic diseases, such as cardiovascular diseases (CVDs), cancer, liver diseases, obesity, diabetes, Alzheimer’s disease, and Parkinson’s disease. This review summarizes the main findings of resveratrol-related health benefits in recent epidemiological surveys, experimental studies, and clinical trials, highlighting its related molecular mechanisms. Resveratrol, therefore, has been regarded as a potent candidate for the development of nutraceuticals and pharmaceuticals to prevent and treat certain chronic diseases.

scholarly journals Safety and efficacy of acetylsalicylic acid in the secondary prevention of cardiovascular diseases in combination with comorbid diseases. COVID-19 treatment options

2021 ◽  
pp. 8-16
Author(s):  
O. A. Tsvetkova ◽  
O. O. Voronkova
Keyword(s):  
Cardiovascular Diseases ◽  
Secondary Prevention ◽  
Acetylsalicylic Acid ◽  
Bronchial Asthma ◽  
Low Dose ◽  
Treatment Options ◽  
Premature Death ◽  
Clinical Complications ◽  
Duration Of Hospitalization ◽  
Comorbid Diseases

Secondary prevention of cardiovascular disease with aspirin is a very important issue. Аcetylsalicylic acid ensures the prevention of premature death, inhibition of progression and the achievement of partial regression of coronary atherosclerosis, prevention of clinical complications and exacerbations of the disease, reduction of the number of cases and the duration of hospitalization. The most promising direction of modern cardiology is considered to be the prevention of cardiovascular diseases (CVD) and their complications (CVD). This is due to two factors: an increase in the life expectancy of the world’s population as a whole and the persistent leadership of coronary heart disease and brain stroke as the leading causes of death, and disability. The pathogenetic aspects of the administration of acetylsalicylic acid are discussed. The most common dosage form of low-dose (ld) preparations of acetylsalicylic acid (ASA) for preventive use is an intestinal-soluble tablet — 80.6% in the structure of ldASK preparations. Low-dose ASK preparations are mainly presented (84.4%) in the form of monopreparations containing only ASA as the active substance, most often at a dose of 100 mg. However, the side effects of aspirin limit drug intake. This is also due to the high frequency of comorbid diseases such as bronchial asthma and stomach ulcer. The article discusses the issue of prescribing acetylsalicylic acid and the possibility of treating patients with concomitant bronchial asthma, gastric ulcer and obesity. The prevalence of gastroduodenal lesions was significantly lower with intestinal-coated ASA than with buffered acetylsalicylic acid. It was demonstrated that endoscopic lesions of the gastroduodenal mucosa were significantly less likely when using intestinal-coated ASA (100 mg / day) than when using conventional аcetylsalicylic acid, and the assessment of the lesion when using intestinalcoated ASA was similar to the assessment of placebo without аcetylsalicylic acid. In addition, the issue of the possibility of including аcetylsalicylic acid in the treatment regimen for COVID 19 is being discussed. 

scholarly journals A Novel Discovery: Holistic Efficacy at the Special Organ Level of Pungent Flavored Compounds from Pungent Traditional Chinese Medicine

2019 ◽  
Vol 20 (3) ◽  
pp. 752 ◽  
Author(s):  
Zhao Chen ◽  
Yanfeng Cao ◽  
Yanling Zhang ◽  
Yanjiang Qiao
Keyword(s):  
Cardiovascular Diseases ◽  
Liver Diseases ◽  
Skin Diseases ◽  
Gastrointestinal Diseases ◽  
Vital Role ◽  
The Body ◽  
Body Parts ◽  
Systems Pharmacology ◽  
Systematic Strategy ◽  
Organ Level

Pungent traditional Chinese medicines (TCMs) play a vital role in the clinical treatment of hepatobiliary disease, gastrointestinal diseases, cardiovascular diseases, diabetes, skin diseases and so on. Pungent TCMs have a vastness of pungent flavored (with pungent taste or smell) compounds. To elucidate the molecular mechanism of pungent flavored compounds in treating cardiovascular diseases (CVDs) and liver diseases, five pungent TCMs with the action of blood-activating and stasis-resolving (BASR) were selected. Here, an integrated systems pharmacology approach is presented for illustrating the molecular correlations between pungent flavored compounds and their holistic efficacy at the special organ level. First, we identified target proteins that are associated with pungent flavored compounds and found that these targets were functionally related to CVDs and liver diseases. Then, based on the phenotype that directly links human genes to the body parts they affect, we clustered target modules associated with pungent flavored compounds into liver and heart organs. We applied systems-based analysis to introduce a pungent flavored compound-target-pathway-organ network that clarifies mechanisms of pungent substances treating cardiovascular diseases and liver diseases by acting on the heart/liver organ. The systems pharmacology also suggests a novel systematic strategy for rational drug development from pungent TCMs in treating cardiovascular disease and associated liver diseases.

The miR-21 potential of serving as a biomarker for liver diseases in clinical practice

2020 ◽  
Vol 48 (5) ◽  
pp. 2295-2305
Author(s):  
Jiawei Zhang ◽  
Dandan Li ◽  
Rui Zhang ◽  
Peng Gao ◽  
Rongxue Peng ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Diseases ◽  
Hepatic Disease ◽  
Noninvasive Detection ◽  
Diagnosis And Prognosis ◽  
Expected Performance ◽  
Potential Biomarker ◽  
Disease Condition ◽  
Complex Regulatory Network

The role of miR-21 in the pathogenesis of various liver diseases, together with the possibility of detecting microRNA in the circulation, makes miR-21 a potential biomarker for noninvasive detection. In this review, we summarize the potential utility of extracellular miR-21 in the clinical management of hepatic disease patients and compared it with the current clinical practice. MiR-21 shows screening and prognostic value for liver cancer. In liver cirrhosis, miR-21 may serve as a biomarker for the differentiating diagnosis and prognosis. MiR-21 is also a potential biomarker for the severity of hepatitis. We elucidate the disease condition under which miR-21 testing can reach the expected performance. Though miR-21 is a key regulator of liver diseases, microRNAs coordinate with each other in the complex regulatory network. As a result, the performance of miR-21 is better when combined with other microRNAs or classical biomarkers under certain clinical circumstances.

Sign in / Sign up

Export Citation Format

Share Document